Human Papillomavirus Vaccines

Successes and Future Challenges

Samara Perez, Gregory Zimet, Ovidiu Tatar, Nathan Stupiansky, William A. Fisher, Zeev Rosberger

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Over a decade has passed since the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received unequivocal backing from the scientific and medical communities, yet continue to be debated in the media and within the general public. The current review is an updated examination that the authors made five years ago on some of the key sociocultural and behavioral issues associated with HPV vaccine uptake and acceptability, given the changing HPV vaccine policies and beliefs worldwide. We explore current worldwide HPV vaccination rates, outline HPV vaccine policies, and revisit critical issues associated with HPV vaccine uptake including: risk compensation, perceptions of vaccine safety and efficacy, age of vaccination, and healthcare provider (HCP) recommendation and communication. While public scrutiny of the vaccine has not subsided, empirical evidence supporting its safety and efficacy beyond preventing cervical cancer has amassed. There are conclusive findings showing no link that vaccinated individuals engage in riskier sexual behaviors as a result of being immunized (risk compensation) both at the individual and at the policy level. Finally, HCP recommendation continues to be a central factor in HPV vaccine uptake. Studies have illuminated how HCP practices and communication enhance uptake and alleviate misperceptions about HPV vaccination. Strategies such as bundling vaccinations, allowing nurses to vaccinate via “standing orders,” and diversifying vaccination settings (e.g., pharmacies) may be effective steps to increase rates. The successes of HPV vaccination outweigh the controversy, but as the incidence of HPV-related cancers rises, it is imperative that future research on HPV vaccine acceptability continues to identify effective and targeted strategies to inform HPV vaccination programs and improve HPV coverage rates worldwide.

Original languageEnglish (US)
Pages (from-to)1385-1396
Number of pages12
JournalDrugs
Volume78
Issue number14
DOIs
StatePublished - Sep 1 2018

Fingerprint

Papillomavirus Vaccines
Vaccination
Vaccines
Health Personnel
Communication
Safety
Pharmacies
Uterine Cervical Neoplasms
Sexual Behavior
Nurses
Incidence

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Human Papillomavirus Vaccines : Successes and Future Challenges. / Perez, Samara; Zimet, Gregory; Tatar, Ovidiu; Stupiansky, Nathan; Fisher, William A.; Rosberger, Zeev.

In: Drugs, Vol. 78, No. 14, 01.09.2018, p. 1385-1396.

Research output: Contribution to journalReview article

Perez, S, Zimet, G, Tatar, O, Stupiansky, N, Fisher, WA & Rosberger, Z 2018, 'Human Papillomavirus Vaccines: Successes and Future Challenges', Drugs, vol. 78, no. 14, pp. 1385-1396. https://doi.org/10.1007/s40265-018-0975-6
Perez, Samara ; Zimet, Gregory ; Tatar, Ovidiu ; Stupiansky, Nathan ; Fisher, William A. ; Rosberger, Zeev. / Human Papillomavirus Vaccines : Successes and Future Challenges. In: Drugs. 2018 ; Vol. 78, No. 14. pp. 1385-1396.
@article{54b9c6296174421d893e2c4b16dfaf5c,
title = "Human Papillomavirus Vaccines: Successes and Future Challenges",
abstract = "Over a decade has passed since the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received unequivocal backing from the scientific and medical communities, yet continue to be debated in the media and within the general public. The current review is an updated examination that the authors made five years ago on some of the key sociocultural and behavioral issues associated with HPV vaccine uptake and acceptability, given the changing HPV vaccine policies and beliefs worldwide. We explore current worldwide HPV vaccination rates, outline HPV vaccine policies, and revisit critical issues associated with HPV vaccine uptake including: risk compensation, perceptions of vaccine safety and efficacy, age of vaccination, and healthcare provider (HCP) recommendation and communication. While public scrutiny of the vaccine has not subsided, empirical evidence supporting its safety and efficacy beyond preventing cervical cancer has amassed. There are conclusive findings showing no link that vaccinated individuals engage in riskier sexual behaviors as a result of being immunized (risk compensation) both at the individual and at the policy level. Finally, HCP recommendation continues to be a central factor in HPV vaccine uptake. Studies have illuminated how HCP practices and communication enhance uptake and alleviate misperceptions about HPV vaccination. Strategies such as bundling vaccinations, allowing nurses to vaccinate via “standing orders,” and diversifying vaccination settings (e.g., pharmacies) may be effective steps to increase rates. The successes of HPV vaccination outweigh the controversy, but as the incidence of HPV-related cancers rises, it is imperative that future research on HPV vaccine acceptability continues to identify effective and targeted strategies to inform HPV vaccination programs and improve HPV coverage rates worldwide.",
author = "Samara Perez and Gregory Zimet and Ovidiu Tatar and Nathan Stupiansky and Fisher, {William A.} and Zeev Rosberger",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s40265-018-0975-6",
language = "English (US)",
volume = "78",
pages = "1385--1396",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "14",

}

TY - JOUR

T1 - Human Papillomavirus Vaccines

T2 - Successes and Future Challenges

AU - Perez, Samara

AU - Zimet, Gregory

AU - Tatar, Ovidiu

AU - Stupiansky, Nathan

AU - Fisher, William A.

AU - Rosberger, Zeev

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Over a decade has passed since the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received unequivocal backing from the scientific and medical communities, yet continue to be debated in the media and within the general public. The current review is an updated examination that the authors made five years ago on some of the key sociocultural and behavioral issues associated with HPV vaccine uptake and acceptability, given the changing HPV vaccine policies and beliefs worldwide. We explore current worldwide HPV vaccination rates, outline HPV vaccine policies, and revisit critical issues associated with HPV vaccine uptake including: risk compensation, perceptions of vaccine safety and efficacy, age of vaccination, and healthcare provider (HCP) recommendation and communication. While public scrutiny of the vaccine has not subsided, empirical evidence supporting its safety and efficacy beyond preventing cervical cancer has amassed. There are conclusive findings showing no link that vaccinated individuals engage in riskier sexual behaviors as a result of being immunized (risk compensation) both at the individual and at the policy level. Finally, HCP recommendation continues to be a central factor in HPV vaccine uptake. Studies have illuminated how HCP practices and communication enhance uptake and alleviate misperceptions about HPV vaccination. Strategies such as bundling vaccinations, allowing nurses to vaccinate via “standing orders,” and diversifying vaccination settings (e.g., pharmacies) may be effective steps to increase rates. The successes of HPV vaccination outweigh the controversy, but as the incidence of HPV-related cancers rises, it is imperative that future research on HPV vaccine acceptability continues to identify effective and targeted strategies to inform HPV vaccination programs and improve HPV coverage rates worldwide.

AB - Over a decade has passed since the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received unequivocal backing from the scientific and medical communities, yet continue to be debated in the media and within the general public. The current review is an updated examination that the authors made five years ago on some of the key sociocultural and behavioral issues associated with HPV vaccine uptake and acceptability, given the changing HPV vaccine policies and beliefs worldwide. We explore current worldwide HPV vaccination rates, outline HPV vaccine policies, and revisit critical issues associated with HPV vaccine uptake including: risk compensation, perceptions of vaccine safety and efficacy, age of vaccination, and healthcare provider (HCP) recommendation and communication. While public scrutiny of the vaccine has not subsided, empirical evidence supporting its safety and efficacy beyond preventing cervical cancer has amassed. There are conclusive findings showing no link that vaccinated individuals engage in riskier sexual behaviors as a result of being immunized (risk compensation) both at the individual and at the policy level. Finally, HCP recommendation continues to be a central factor in HPV vaccine uptake. Studies have illuminated how HCP practices and communication enhance uptake and alleviate misperceptions about HPV vaccination. Strategies such as bundling vaccinations, allowing nurses to vaccinate via “standing orders,” and diversifying vaccination settings (e.g., pharmacies) may be effective steps to increase rates. The successes of HPV vaccination outweigh the controversy, but as the incidence of HPV-related cancers rises, it is imperative that future research on HPV vaccine acceptability continues to identify effective and targeted strategies to inform HPV vaccination programs and improve HPV coverage rates worldwide.

UR - http://www.scopus.com/inward/record.url?scp=85054307228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054307228&partnerID=8YFLogxK

U2 - 10.1007/s40265-018-0975-6

DO - 10.1007/s40265-018-0975-6

M3 - Review article

VL - 78

SP - 1385

EP - 1396

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 14

ER -